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Institute, Harvard Medical School, Boston; 2Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge,
Cambridge; and 3Departments of Medicine and Genetics, University of Washington, Seattle
The autosomal dominantly inherited hamartoma poly-
posis syndromes comprise juvenile polyposis syndrome
or juvenile polyposis coli (JPS; OMIM174900), Cowden
syndrome (CS; OMIM 158350), Bannayan-Ruvalcaba-
Riley syndrome (BRR; OMIM 153480), and Peutz-Jegh-
ers syndrome (PJS; OMIM174900). Themolecular basis
of these syndromes has remained elusive until recently,
in part because of the often subtle clinical distinctions
among them. Since the risk of organ-specific cancers in
each syndrome is different, a more reliable and objective
means of differentiating among these syndromes would
be desirable, such as one based on molecular diagnosis.
The first syndrome to yield to genetic analysis was CS,
characterized by multiple hamartomas, including gas-
trointestinal hamartomatous polyps, and a high risk of
benign and malignant neoplasms of the thyroid, breast,
uterus, and skin (Eng and Parsons 1998). In 1996, CS
was mapped to 10q22-24 (Nelen et al. 1996). The fol-
lowing year, germ-line mutations in PTEN/MMAC1/
TEP1, encoding an ubiquitously expressed dual speci-
ficity phosphatase, were found in CS (see table 1; Li and
Sun 1997; Li et al. 1997; Liaw et al. 1997; Steck et al.
1997). A fewmonths later, germ-line mutations inPTEN
were also noted in BRR, a congenital syndrome char-
acterized by macrocephaly, lipomatosis, hamartomatous
polyposis, hemangiomas, and speckled penis (Marsh et
al. 1997a). From these data, one could conclude that CS
and BRR are at least allelic and might even be one and
the same syndrome along a broad spectrum. Buoyed by
an early hope that PTEN would be the susceptibility
gene for all inherited hamartoma polyposis syndromes,
investigators rushed to their freezers to pull out samples
from PJS and JPS cases. However, the identification of
LKB1/STK11, mapping to 19p13.3, as the basis for PJS
(see table 1; Hemminki et al. 1998; Jenne et al. 1998)
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demonstrated that this hopeful model was incorrect, but
the etiology of JPS remained contentious.
Attention, therefore, turned to JPS. JPS is character-
ized mainly by the presence of gastrointestinal hamar-
tomatous polyps and an increased risk of gastrointestinal
malignancy. The diagnosis of JPS is made only if features
classic for other syndromes are not present. Preliminary
genetic data seemed more than suggestive: somatic data
pointed to the existence of a putative locus for JPS, called
JP1, at 10q22-24 encompassing PTEN, although fine
structure mapping placed this locus centromeric to
PTEN (Jacoby et al. 1997). These findings were suffi-
cient to induce several groups to pursue PTEN as a
candidate for JP1, with confusing results. Three studies,
including one published in this issue of the Journal, com-
prising a total of 21 classic JPS families and 16 sporadic
cases, were found not to have any germ-line PTEN mu-
tation (Marsh et al. 1997b; Howe et al. 1998 [in this
issue]; http://128.220.85.41:5002/MCGI/SEND1^
WEBUTLTY(1378,1)/1674326758). In addition, the
10q22-24 region could be excluded as a putative JPS
locus in 15 of these families by linkage analysis (Marsh
et al. 1997b;Howe et al. 1998). Recently, three unrelated
JPS cases were reported to harbor germ-line PTEN
mutations (Olschwang et al. 1998). Interestingly, the
adult male patient (G116) with gastrointestinal hamar-
tomatous polyps also had laryngeal carcinoma and a
heterogeneous thyroid nodule. Clinically, the presence
of hamartomatous polyps, laryngeal carcinoma, and a
heterogeneous thyroid nodule is highly suggestive of CS.
Unfortunately, insufficient clinical detail, especially the
dermatologic examination, was reported. The two chil-
dren (G796 and G710), respectively diagnosed at ages
14 and 3 years (current age 10), were reported not to
have manifestations of CS or BRR (Olschwang et al.
1998). CS carries an age-related penetrance: 90% by the
age of 20 years and well under 10% below age 15 years
(Nelen et al. 1996). Indeed, initial linkage studies ex-
cluded all cases under the age of 20 years, because pen-
etrance is known to be low under the age of 20 years
(Nelen et al. 1996). Because of the presence of germ-
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Table 1
Genes Involved in the Inherited Hamartomatous Polyposis
Syndromes
Syndrome Localization Susceptibility Gene Reference
CS .. . . . . . . 10q23.3 PTEN See text
BRR .. . . . . 10q23.3
Other
PTEN
?
Marsh et al. (1997a)
PJS . . . . . . . 19p13.3
19q13.4?
LKB1/STK11
?
See text
Mehenni et al. (1997)
JPS . . . . . . . 18q21.1
6q?
Others
?
?
?
Howe et al. (1998)
Thomas et al. (1996)
line PTENmutations, these two children may eventually
develop other features that could be clinically diagnostic
of CS, and they should not be diagnosed as JPS until it
is clear that they lack other features typical of CS as
adults. A similar theme is underscored by another study
that ascertained a family with JPS, but with germ-line
PTENmutation, R334X (Lynch et al. 1997). On further
clinical investigation, the affected members of this family
were found to have macrocephaly, small bowel hamar-
tomatous polyps, small intestinal carcinoma, and skin
lesions typical of CS. In addition, the affected adult had
small intestinal adenocarcinoma. The presence of classic
clinical features that agree with the diagnostic criteria
of the International Cowden Consortium (Eng and Par-
sons 1998) and the presence of a germ-line PTEN mu-
tation argue convincingly for a single, unifying diagnosis
of CS for this family.
Because phenotypic features may be shared by several
hamartoma syndromes and the clinical diagnosis is not
straightforward, only physicians with extensive experi-
ence with these disorders may be able to distinguish
reliably among these disorders. Diagnosis is even less
straightforward if it is a diagnosis of exclusion, as is the
case for JPS. It is important to distinguish the various
hamartoma syndromes, as the predisposition to cancer
or the types of cancers might be quite different among
them. Therefore, we propose that the presence of a germ-
line PTENmutation is a useful molecular diagnostic sign
for CS or BRR. If a JPS patient is found to harbor an
occult germ-line PTEN mutation, the clinician should
consider CS or BRR as the diagnosis and should monitor
the skin, thyroid, breast, and uterus for cancer
development.
What of the inherited hamartoma syndromes that are
characterized by germ-line PTEN mutation? Depending
on the study one reads, the PTEN mutation frequency
ranges from a low of ∼10% (Tsou et al. 1997) to a high
of ∼80% (Liaw et al. 1997; Marsh et al. 1998), with
varying frequencies in between (Lynch et al. 1997). All
of these studies state adherance to the International
Cowden Consortium operational diagnostic criteria for
CS (Eng and Parsons 1998). However, on close scrutiny,
the studies that ascertain CS through strict adherence to
these criteria have reported the highest mutation fre-
quency (Liaw et al. 1997; Marsh et al. 1998). That these
studies have been the most reproducible suggests that
the operational criteria are robust. Similarly, approxi-
mately half of all BRR cases ascertained by the minimal
features of congenital macrocephaly, lipomatosis, and
speckled penis (with or without intestinal hamartoma-
tous polyposis) have been found to carry germ-line
PTEN mutation (Marsh et al. 1998). There are at least
two JPS patients described to have constitutional de-
letion encompassing 10q23 and PTEN (Jacoby et al.
1997; Tsuchiya et al. 1998). The patient described by
Jacoby et al. (1997) also had dysmorphic features and
microcephaly. It is unclear whether this patient can really
be clinically classified as classic JPS. The second patient
described by Tsuchiya et al. (1998) clearly has the clin-
ical features diagnostic for BRR. Corroborating this, this
patient had a deletion 10q23.2-23.33, a mere 5 cM en-
compassing PTEN (Tsuchiya et al. 1998). This case is
reminiscent of that of Arch et al. (1998), who first de-
scribed a BRR case in the setting of a 10q deletion that
encompasses PTEN. In summary, therefore, finding a
germ-line PTEN mutation is molecular evidence for the
diagnosis of CS or BRR. The absence of an identifiable
PTEN mutation is, for now, nondiagnostic. Much work
still needs to be done in the field of inherited hamartoma
syndromes before a comprehensive molecular classifi-
cation can be attained. The work of Howe et al. (1998)
localizing a JPS locus to 18q is yet another step toward
this goal.
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